Compare Ascendis Pharma A/S (ASND) vs Lemonade Inc (LMND) Price & Performance

Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.

The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.

Lemonade (LMND) trades at $70.51, up 0.26% today, with a bullish technical signal from moving averages and strong support at $69. The company shows accelerating revenue growth, with 2025 revenue reaching $738 million, while narrowing net losses to -$166 million. Recent news highlights expansion into new states and reinsurance program improvements, though the stock faces a mixed analyst consensus with 33% buy ratings.

Outlook remains speculative given persistent losses but improving margins; key opportunities include AI-driven growth and market expansion, while risks involve high valuation multiples and profitability timeline uncertainty. The consensus price target of $67 suggests limited near-term upside from current levels.